Ribomic Announces Completion of Patient Enrollment in Early Phase II Study of Umedaptanib Pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study
Ribomic宣佈Umedaptanib Pegol用於軟骨發育不全症（Achondroplasia）的早期II期研究患者招募已完成，並啓動早期II期臨床研究2隊的劑量給藥。
